Last 12 months
Inside the activity.
3 purchase rows · 2 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 3 | 1 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 27, 2021 Filed Mar 2, 2021 22:35 UTC |
Carapezzi William R JRExecutive Vice President
|
Exercise / conversionStock Appreciation Rights · Derivative | 21,570 | $0.00 Strike: $22.35 | $0.00 |
DisclosureSEC source: 0001225208-21-004301 · doc4.xml · derivative · entry 5 Carapezzi William R JR · CIK 0001295078 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,570 shares Expires 2021-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 27, 2021 Filed Mar 2, 2021 22:35 UTC |
Carapezzi William R JRExecutive Vice President
|
Tax withholdingCommon Stock | 13,676 | $34.64 | $473,736.64 |
DisclosureSEC source: 0001225208-21-004301 · doc4.xml · nonDerivative · entry 3 Carapezzi William R JR · CIK 0001295078 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,861 F4 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F5 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document |
| February 27, 2021 Filed Mar 2, 2021 22:35 UTC |
Carapezzi William R JRExecutive Vice President
|
Tax withholdingCommon Stock | 2,985 | $33.49 | $99,967.65 |
DisclosureSEC source: 0001225208-21-004301 · doc4.xml · nonDerivative · entry 2 Carapezzi William R JR · CIK 0001295078 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,537 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. F3 · price: Price is the closing price of Pfizer common stock on February 26, 2021. Read SEC document |
| February 27, 2021 Filed Mar 2, 2021 22:35 UTC |
Carapezzi William R JRExecutive Vice President
|
Exercise / conversionCommon Stock | 21,570 | $22.35 | $482,089.50 |
DisclosureSEC source: 0001225208-21-004301 · doc4.xml · nonDerivative · entry 1 Carapezzi William R JR · CIK 0001295078 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,522 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 27, 2021 Filed Mar 2, 2021 22:35 UTC |
DAMELIO FRANK AExecutive Vice President
|
Exercise / conversionStock Appreciation Rights · Derivative | 152,785 | $0.00 Strike: $22.35 | $0.00 |
DisclosureSEC source: 0001225208-21-004302 · doc4.xml · derivative · entry 4 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 152,785 shares Expires 2021-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 27, 2021 Filed Mar 2, 2021 22:35 UTC |
DAMELIO FRANK AExecutive Vice President
|
Tax withholdingCommon Stock | 96,872 | $34.64 | $3,355,646.08 |
DisclosureSEC source: 0001225208-21-004302 · doc4.xml · nonDerivative · entry 3 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 483,188 F4 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F5 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document |
| February 27, 2021 Filed Mar 2, 2021 22:35 UTC |
DAMELIO FRANK AExecutive Vice President
|
Tax withholdingCommon Stock | 27,381 | $33.49 | $916,989.69 |
DisclosureSEC source: 0001225208-21-004302 · doc4.xml · nonDerivative · entry 2 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 580,060 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. F3 · price: Price is the closing price of Pfizer common stock on February 26, 2021. Read SEC document |
| February 27, 2021 Filed Mar 2, 2021 22:35 UTC |
DAMELIO FRANK AExecutive Vice President
|
Exercise / conversionCommon Stock | 152,785 | $22.35 | $3,414,744.75 |
DisclosureSEC source: 0001225208-21-004302 · doc4.xml · nonDerivative · entry 1 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 607,441 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 27, 2021 Filed Mar 2, 2021 22:35 UTC |
DAMICO JENNIFER B.SVP & Controller
|
Exercise / conversionStock Appreciation Rights · Derivative | 9,886 | $0.00 Strike: $22.35 | $0.00 |
DisclosureSEC source: 0001225208-21-004303 · doc4.xml · derivative · entry 4 DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,886 shares Expires 2021-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 27, 2021 Filed Mar 2, 2021 22:35 UTC |
DAMICO JENNIFER B.SVP & Controller
|
Tax withholdingCommon Stock | 6,268 | $34.64 | $217,123.52 |
DisclosureSEC source: 0001225208-21-004303 · doc4.xml · nonDerivative · entry 3 DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,248 F4 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F5 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document |
| February 27, 2021 Filed Mar 2, 2021 22:35 UTC |
DAMICO JENNIFER B.SVP & Controller
|
Tax withholdingCommon Stock | 1,229 | $33.49 | $41,159.21 |
DisclosureSEC source: 0001225208-21-004303 · doc4.xml · nonDerivative · entry 2 DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,516 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. F3 · price: Price is the closing price of Pfizer common stock on February 26, 2021. Read SEC document |
| February 27, 2021 Filed Mar 2, 2021 22:35 UTC |
DAMICO JENNIFER B.SVP & Controller
|
Exercise / conversionCommon Stock | 9,886 | $22.35 | $220,952.10 |
DisclosureSEC source: 0001225208-21-004303 · doc4.xml · nonDerivative · entry 1 DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,745 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 27, 2021 Filed Mar 2, 2021 22:35 UTC |
Hwang AngelaGroup President
|
Exercise / conversionStock Appreciation Rights · Derivative | 9,886 | $0.00 Strike: $22.35 | $0.00 |
DisclosureSEC source: 0001225208-21-004304 · doc4.xml · derivative · entry 6 Hwang Angela · CIK 0001725474 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,886 shares Expires 2021-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 27, 2021 Filed Mar 2, 2021 22:35 UTC |
Hwang AngelaGroup President
|
Tax withholdingCommon Stock | 6,268 | $34.64 | $217,123.52 |
DisclosureSEC source: 0001225208-21-004304 · doc4.xml · nonDerivative · entry 3 Hwang Angela · CIK 0001725474 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,171 F4 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F5 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document |
| February 27, 2021 Filed Mar 2, 2021 22:35 UTC |
Hwang AngelaGroup President
|
Tax withholdingCommon Stock | 1,772 | $33.49 | $59,344.28 |
DisclosureSEC source: 0001225208-21-004304 · doc4.xml · nonDerivative · entry 2 Hwang Angela · CIK 0001725474 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,439 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. F3 · price: Price is the closing price of Pfizer common stock on February 26, 2021. Read SEC document |
| February 27, 2021 Filed Mar 2, 2021 22:35 UTC |
Hwang AngelaGroup President
|
Exercise / conversionCommon Stock | 9,886 | $22.35 | $220,952.10 |
DisclosureSEC source: 0001225208-21-004304 · doc4.xml · nonDerivative · entry 1 Hwang Angela · CIK 0001725474 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,211 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 27, 2021 Filed Mar 2, 2021 22:59 UTC |
JOHNSON RADY AExecutive Vice President
|
Exercise / conversionStock Appreciation Rights · Derivative | 25,165 | $0.00 Strike: $22.35 | $0.00 |
DisclosureSEC source: 0001225208-21-004319 · doc4.xml · derivative · entry 5 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,165 shares Expires 2021-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 27, 2021 Filed Mar 2, 2021 22:59 UTC |
JOHNSON RADY AExecutive Vice President
|
Tax withholdingCommon Stock | 15,955 | $34.64 | $552,681.20 |
DisclosureSEC source: 0001225208-21-004319 · doc4.xml · nonDerivative · entry 3 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,844 F4 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F5 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document |
| February 27, 2021 Filed Mar 2, 2021 22:59 UTC |
JOHNSON RADY AExecutive Vice President
|
Tax withholdingCommon Stock | 4,510 | $33.49 | $151,039.90 |
DisclosureSEC source: 0001225208-21-004319 · doc4.xml · nonDerivative · entry 2 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,799 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. F3 · price: Price is the closing price of Pfizer common stock on February 26, 2021. Read SEC document |
| February 27, 2021 Filed Mar 2, 2021 22:59 UTC |
JOHNSON RADY AExecutive Vice President
|
Exercise / conversionCommon Stock | 25,165 | $22.35 | $562,437.75 |
DisclosureSEC source: 0001225208-21-004319 · doc4.xml · nonDerivative · entry 1 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,309 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 27, 2021 Filed Mar 2, 2021 23:00 UTC |
LANKLER DOUGLAS MExecutive Vice President
|
Exercise / conversionStock Appreciation Rights · Derivative | 53,925 | $0.00 Strike: $22.35 | $0.00 |
DisclosureSEC source: 0001225208-21-004320 · doc4.xml · derivative · entry 5 LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 53,925 shares Expires 2021-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 27, 2021 Filed Mar 2, 2021 23:00 UTC |
LANKLER DOUGLAS MExecutive Vice President
|
Tax withholdingCommon Stock | 34,191 | $34.64 | $1,184,376.24 |
DisclosureSEC source: 0001225208-21-004320 · doc4.xml · nonDerivative · entry 3 LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,317 F4 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F5 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document |
| February 27, 2021 Filed Mar 2, 2021 23:00 UTC |
LANKLER DOUGLAS MExecutive Vice President
|
Tax withholdingCommon Stock | 9,664 | $33.49 | $323,647.36 |
DisclosureSEC source: 0001225208-21-004320 · doc4.xml · nonDerivative · entry 2 LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,508 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. F3 · price: Price is the closing price of Pfizer common stock on February 26, 2021. Read SEC document |
| February 27, 2021 Filed Mar 2, 2021 23:00 UTC |
LANKLER DOUGLAS MExecutive Vice President
|
Exercise / conversionCommon Stock | 53,925 | $22.35 | $1,205,223.75 |
DisclosureSEC source: 0001225208-21-004320 · doc4.xml · nonDerivative · entry 1 LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,172 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 27, 2021 Filed Mar 2, 2021 22:59 UTC |
MACKENZIE ALEXANDER RExecutive Vice President
|
Exercise / conversionStock Appreciation Rights · Derivative | 29,838 | $0.00 Strike: $22.35 | $0.00 |
DisclosureSEC source: 0001225208-21-004321 · doc4.xml · derivative · entry 5 MACKENZIE ALEXANDER R · CIK 0001678459 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 29,838 shares Expires 2021-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 27, 2021 Filed Mar 2, 2021 22:59 UTC |
MACKENZIE ALEXANDER RExecutive Vice President
|
Tax withholdingCommon Stock | 18,919 | $34.64 | $655,354.16 |
DisclosureSEC source: 0001225208-21-004321 · doc4.xml · nonDerivative · entry 3 MACKENZIE ALEXANDER R · CIK 0001678459 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,607 F4 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F5 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document |
| February 27, 2021 Filed Mar 2, 2021 22:59 UTC |
MACKENZIE ALEXANDER RExecutive Vice President
|
Tax withholdingCommon Stock | 5,812 | $33.49 | $194,643.88 |
DisclosureSEC source: 0001225208-21-004321 · doc4.xml · nonDerivative · entry 2 MACKENZIE ALEXANDER R · CIK 0001678459 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,526 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. F3 · price: Price is the closing price of Pfizer common stock on February 26, 2021. Read SEC document |
| February 27, 2021 Filed Mar 2, 2021 22:59 UTC |
MACKENZIE ALEXANDER RExecutive Vice President
|
Exercise / conversionCommon Stock | 29,838 | $22.35 | $666,879.30 |
DisclosureSEC source: 0001225208-21-004321 · doc4.xml · nonDerivative · entry 1 MACKENZIE ALEXANDER R · CIK 0001678459 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,338 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 27, 2021 Filed Mar 2, 2021 22:59 UTC |
SUSMAN SALLYExecutive Vice President
|
Exercise / conversionStock Appreciation Rights · Derivative | 71,899 | $0.00 Strike: $22.35 | $0.00 |
DisclosureSEC source: 0001225208-21-004322 · doc4.xml · derivative · entry 5 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 71,899 shares Expires 2021-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 27, 2021 Filed Mar 2, 2021 22:59 UTC |
SUSMAN SALLYExecutive Vice President
|
Tax withholdingCommon Stock | 45,587 | $34.64 | $1,579,133.68 |
DisclosureSEC source: 0001225208-21-004322 · doc4.xml · nonDerivative · entry 3 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,883 F4 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F5 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document |
| February 27, 2021 Filed Mar 2, 2021 22:59 UTC |
SUSMAN SALLYExecutive Vice President
|
Tax withholdingCommon Stock | 14,004 | $33.49 | $468,993.96 |
DisclosureSEC source: 0001225208-21-004322 · doc4.xml · nonDerivative · entry 2 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,470 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. F3 · price: Price is the closing price of Pfizer common stock on February 26, 2021. Read SEC document |
| February 27, 2021 Filed Mar 2, 2021 22:59 UTC |
SUSMAN SALLYExecutive Vice President
|
Exercise / conversionCommon Stock | 71,899 | $22.35 | $1,606,942.65 |
DisclosureSEC source: 0001225208-21-004322 · doc4.xml · nonDerivative · entry 1 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,474 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 27, 2021 Filed Mar 2, 2021 22:59 UTC |
YOUNG JOHN DGroup President
|
Exercise / conversionStock Appreciation Rights · Derivative | 129,419 | $0.00 Strike: $22.35 | $0.00 |
DisclosureSEC source: 0001225208-21-004323 · doc4.xml · derivative · entry 6 YOUNG JOHN D · CIK 0001551792 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 129,419 shares Expires 2021-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 27, 2021 Filed Mar 2, 2021 22:59 UTC |
YOUNG JOHN DGroup President
|
Tax withholdingCommon Stock | 82,057 | $34.64 | $2,842,454.48 |
DisclosureSEC source: 0001225208-21-004323 · doc4.xml · nonDerivative · entry 3 YOUNG JOHN D · CIK 0001551792 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 470,031 F4 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F5 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document |
| February 27, 2021 Filed Mar 2, 2021 22:59 UTC |
YOUNG JOHN DGroup President
|
Tax withholdingCommon Stock | 23,194 | $33.49 | $776,767.06 |
DisclosureSEC source: 0001225208-21-004323 · doc4.xml · nonDerivative · entry 2 YOUNG JOHN D · CIK 0001551792 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 552,088 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. F3 · price: Price is the closing price of Pfizer common stock on February 26, 2021. Read SEC document |
| February 27, 2021 Filed Mar 2, 2021 22:59 UTC |
YOUNG JOHN DGroup President
|
Exercise / conversionCommon Stock | 129,419 | $22.35 | $2,892,514.65 |
DisclosureSEC source: 0001225208-21-004323 · doc4.xml · nonDerivative · entry 1 YOUNG JOHN D · CIK 0001551792 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 575,282 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 27, 2021 Filed Mar 3, 2021 00:00 UTC |
Dolsten MikaelPresident R&D
|
Tax withholdingCommon Stock | 23,841 | $33.49 | $798,435.09 |
DisclosureSEC source: 0001225208-21-004333 · doc4.xml · nonDerivative · entry 1 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,727 F1 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the settlement of stock units from previously exercised stock appreciation rights (including dividend equivalents thereon). F2 · price: Price is the closing price of Pfizer common stock on February 26, 2021. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 20:58 UTC |
BOURLA ALBERTDirector · Chairman & CEO
|
GrantStock Appreciation Rights · Derivative | 424,782 | $0.00 Strike: $33.82 | $0.00 |
DisclosureSEC source: 0001225208-21-004031 · doc4.xml · derivative · entry 7 BOURLA ALBERT · CIK 0001595703 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 424,782 Underlying: Common Stock · 424,782 shares Expires 2028-02-25 F6 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F6 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 20:58 UTC |
BOURLA ALBERTDirector · Chairman & CEO
|
GrantStock Appreciation Rights · Derivative | 491,626 | $0.00 Strike: $33.82 | $0.00 |
DisclosureSEC source: 0001225208-21-004031 · doc4.xml · derivative · entry 6 BOURLA ALBERT · CIK 0001595703 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 491,626 Underlying: Common Stock · 491,626 shares Expires 2026-02-25 F5 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F5 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 20:58 UTC |
BOURLA ALBERTDirector · Chairman & CEO
|
Exercise / conversionStock Appreciation Rights · Derivative | 163,334 | $0.00 Strike: $22.86 | $0.00 |
DisclosureSEC source: 0001225208-21-004031 · doc4.xml · derivative · entry 5 BOURLA ALBERT · CIK 0001595703 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 163,334 shares Expires 2021-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 20:58 UTC |
BOURLA ALBERTDirector · Chairman & CEO
|
Tax withholdingCommon Stock | 105,707 | $34.76 | $3,674,375.32 |
DisclosureSEC source: 0001225208-21-004031 · doc4.xml · nonDerivative · entry 3 BOURLA ALBERT · CIK 0001595703 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,109 F3 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F4 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 20:58 UTC |
BOURLA ALBERTDirector · Chairman & CEO
|
Tax withholdingCommon Stock | 28,221 | $33.82 | $954,434.22 |
DisclosureSEC source: 0001225208-21-004031 · doc4.xml · nonDerivative · entry 2 BOURLA ALBERT · CIK 0001595703 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,816 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 20:58 UTC |
BOURLA ALBERTDirector · Chairman & CEO
|
Exercise / conversionCommon Stock | 163,334 | $22.86 | $3,733,815.24 |
DisclosureSEC source: 0001225208-21-004031 · doc4.xml · nonDerivative · entry 1 BOURLA ALBERT · CIK 0001595703 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,037 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 20:55 UTC |
DAMICO JENNIFER B.SVP & Controller
|
GrantStock Appreciation Rights · Derivative | 15,171 | $0.00 Strike: $33.82 | $0.00 |
DisclosureSEC source: 0001225208-21-004024 · doc4.xml · derivative · entry 7 DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,171 Underlying: Common Stock · 15,171 shares Expires 2028-02-25 F7 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F7 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 20:55 UTC |
DAMICO JENNIFER B.SVP & Controller
|
GrantStock Appreciation Rights · Derivative | 17,558 | $0.00 Strike: $33.82 | $0.00 |
DisclosureSEC source: 0001225208-21-004024 · doc4.xml · derivative · entry 6 DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,558 Underlying: Common Stock · 17,558 shares Expires 2026-02-25 F6 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F6 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 20:55 UTC |
DAMICO JENNIFER B.SVP & Controller
|
Exercise / conversionStock Appreciation Rights · Derivative | 12,477 | $0.00 Strike: $22.89 | $0.00 |
DisclosureSEC source: 0001225208-21-004024 · doc4.xml · derivative · entry 5 DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,477 shares Expires 2021-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 20:55 UTC |
DAMICO JENNIFER B.SVP & Controller
|
Tax withholdingCommon Stock | 8,075 | $34.76 | $280,687.00 |
DisclosureSEC source: 0001225208-21-004024 · doc4.xml · nonDerivative · entry 4 DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,859 F4 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F5 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 20:55 UTC |
DAMICO JENNIFER B.SVP & Controller
|
Tax withholdingCommon Stock | 1,496 | $33.82 | $50,594.72 |
DisclosureSEC source: 0001225208-21-004024 · doc4.xml · nonDerivative · entry 3 DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,934 F3 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 20:55 UTC |
DAMICO JENNIFER B.SVP & Controller
|
GrantCommon Stock | 3,649 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-004024 · doc4.xml · nonDerivative · entry 2 DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,430 F2 · shares: The reported transaction constitutes the grant of restricted stock units, which are subject to certain vesting requirements. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 20:55 UTC |
DAMICO JENNIFER B.SVP & Controller
|
Exercise / conversionCommon Stock | 12,477 | $22.89 | $285,598.53 |
DisclosureSEC source: 0001225208-21-004024 · doc4.xml · nonDerivative · entry 1 DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,781 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.